Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|April 28, 2011

StudyManager Unveils Reveal Version 3.2

StudyManager

announced the release of Reveal 3.2, with enhanced features that provide greater ease of use and performance for research sites, academic medical centers, and hospitals.Reveal 3.2 provides a host of enhanced features focused on greater ease of use and performance including:

  • Expanded fields and filters available in Reveal’s reporting tool, allowing clients to include and combine additional patient, scheduling, and financial information on custom views and then export them to Microsoft Excel

  • A new, workflow-driven accrual activity “wizard,” making it easier for clients to track their revenue and receivables, create invoices, trigger holdbacks, and apply payments

  • Increased performance of numerous key screens, including the Study “Visits & Procedures” screen, allowing clients to more quickly build their study schedule of events in a grid-style format that matches Sponsor documents

  • A number of new workflow enhancements requested by clients, such as a new study search/select field that allows users to more quickly identify and select a study for patient enrollment

    Reveal features focus on helping sites centralize study information, and:

  • Improve clinical trial recruitment and enrollment results

  • Negotiate more favorable contracts

  • Ensure payment for all study activity–including items that have been historically difficult for sites to track such as screen-fails, holdbacks, and one-time fees

  • Support clinical trial compliance efforts including federal patient privacy regulations, clinical compliance with sponsors’ protocols, and billing compliance to eliminate potential for double-billing of multiple payers

  • Develop best practices and automate daily tasks to save time, reduce stress, and cut down on mistakes

Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.